Platelet Aggregation Devices Market: By Product (Systems, Reagents, Consumables, and Accessories), By Application (Clinical Applications, Research Applications), By End-user (Hospitals, Diagnostic Laboratories, Other End Users) and Geography    

Platelet Aggregation Devices Market size was valued at USD 479.6 million in 2022 and is poised to grow at a significant CAGR of 8.5% over 2023-2029. The platelet aggregation test contains venepuncture in a non-clotting medium made by centrifugation for separating the plasma. In this procedure, aggregometry is also used. The platelet aggregation procedure includes various medical devices that offer precise control over the active blood flow and thus monitor the formation of a platelet thrombus. Platelet aggregation devices contain devices such as platelet function analyzer (PFA), aggregometer, platelet collection systems, and platelet function centrifuge. Based on the product, the platelet aggregation devices market is segmented into systems, reagents, consumables, and accessories.

The Systems segment is anticipated to grow at a significant CAGR over the forecast years owing to the increasing automation of platelet aggregation testing procedures and growing adoption and market preference for automated instruments among diagnostic laboratories. The increasing problem of bleeding conditions is projected to raise the demand for platelet aggregation systems, as these are used to diagnose bleeding conditions. As per the data provided by Genetic Home Reference updates from July 2022, immune thrombocytopenia was projected at 4 per 100,000 in children and 3 per 100,000 in adults around the globe in 2020. The rising prevalence of chronic diseases, the growing elderly population, and technical improvements in platelet aggregation devices are the main drivers of the market.  

Platelet Aggregation Devices Market Key Developments:

• In May 2022, the manufacturer of hemostasis diagnostic tools, Precision Biologic Inc., announced the introduction of their new cry check Chromogenic Factor IX test in Canada, European Union, the United Kingdom, Australia, and New Zealand.